Avenue Therapeutics, Inc. (ATXI)
$0.2601
-0.06 (-19.60%)
Rating:
Recommendation:
Buy
| Symbol | ATXI |
|---|---|
| Price | $0.2601 |
| Beta | 1.052 |
| Volume Avg. | 0.37M |
| Market Cap | 5.757M |
| Shares () | - |
| 52 Week Range | 0.2-2.81 |
| 1y Target Est | - |
| DCF Unlevered | ATXI DCF -> | |
|---|---|---|
| DCF Levered | ATXI LDCF -> | |
| ROE | -813.75% | Strong Sell |
| ROA | -529.60% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 68.77% | Buy |
| P/E | - | |
| P/B | 4.70 | Strong Buy |
Latest ATXI news
About
Download (Excel)Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.